Form 4: Avalo Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 679 shares of common stock on August 10, 2026 for $20.00 per share.
Summary
- Option exercise/conversion: acquired 679 Common Stock at $8.04 ($5,459) on August 10, 2026; holds 52,455 after (Direct).
- Open-market sale: disposed of 679 Common Stock at $20.00 ($13,580) on August 10, 2026; holds 51,776 after (Direct).
- Option exercise/conversion: disposed of 679 Stock Option (Right to Buy) on August 10, 2026; holds 114,413 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $13,580 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mittie Doyle — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 679 | $8 | $5.5K | 52,455 |
| 2026-08-10 | Open-market sale | Common Stock | 679 | $20 | $13.6K | 51,776 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 679 | — | — | 114,413 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (679 shares) |
| 2026-08-10 | Open-market sale (679 shares) |
| 2026-08-10 | Option exercise/conversion (679 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., bearish, Mittie Doyle
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.